Dominant-Negative p53 Mutations Selected in Yeast Hit Cancer Hot Spots
Brachmann, Rainer K., Vidal, Marc, Boeke, Jef D.
Published in Proceedings of the National Academy of Sciences - PNAS (30.04.1996)
Published in Proceedings of the National Academy of Sciences - PNAS (30.04.1996)
Get full text
Journal Article
A Global Suppressor Motif for p53 Cancer Mutants
Baroni, Timothy E., Wang, Ting, Qian, Hua, Dearth, Lawrence R., Truong, Lan N., Zeng, Jue, Denes, Alec E., Chen, Stephanie W., Brachmann, Rainer K., Korsmeyer, Stanley J.
Published in Proceedings of the National Academy of Sciences - PNAS (06.04.2004)
Published in Proceedings of the National Academy of Sciences - PNAS (06.04.2004)
Get full text
Journal Article
hADA3 is required for p53 activity
Wang, Ting, Kobayashi, Takahiko, Takimoto, Rishu, Denes, Alec E., Snyder, Eric L., el-Deiry, Wafik S., Brachmann, Rainer K.
Published in The EMBO journal (15.11.2001)
Published in The EMBO journal (15.11.2001)
Get full text
Journal Article
Functional census of mutation sequence spaces: the example of p53 cancer rescue mutants
Danziger, S.A., Swamidass, S.J., Jue Zeng, Dearth, L.R., Qiang Lu, Chen, J.H., Cheng, J., Hoang, V.P., Saigo, H., Luo, R., Baldi, P., Brachmann, R.K., Lathrop, R.H.
Published in IEEE/ACM transactions on computational biology and bioinformatics (01.04.2006)
Published in IEEE/ACM transactions on computational biology and bioinformatics (01.04.2006)
Get full text
Journal Article
A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC)
Besse, B., Soria, J., Gomez-Roca, C., Ware, J. A., Adjei, A. A., Dy, G. K., Shankar, G., Brachmann, R. K., Groen, H. J.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors
Weekes, C. D., LoRusso, P., Ramakrishnan, V., Shih, L. M., Darbonne, W. C., Hegde, P., Xin, Y., Yu, R., Xiang, H., Brachmann, R. K., Patnaik, A.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors
Weekes, C. D., Hegde, P., Xin, Y., Yu, R., Xiang, H., Beeram, M., Gore, L., Brachmann, R. K., Patnaik, A.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article
A phase Ib study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously in combination with bevacizumab with or without weekly paclitaxel in patients with advanced solid tumors
Patnaik, A., Weekes, C. D., Hegde, P., Xin, Y., Yu, R., Xiang, H., Brachmann, R. K., LoRusso, P.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article
Mechanism for platelet reduction in anti-neuropilin-1 (MNRP1685A)–treated phase I patients
Darbonne, W. C., Du, X., Dhawan, P., Hartley, D., Tarrant, J., Taylor, H., Cain, G., Shih, L. M., Brachmann, R. K., Phung, Q., Weekes, C. D., LoRusso, P., Patnaik, A., Xiang, H., Ramakrishnan, V.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Pharmacodynamic biomarkers of anti-NRP1 activity in phase I, dose-escalating clinical trials as a single agent and combined with bevacizumab
Yan, Y., Li, J., Wu, J., Xin, Y., Aimi, J., Xiang, H., Bagri, A., Brachmann, R. K., Chen, D. S., Hegde, P.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article
Overexpression of the oncoprotein prothymosin α triggers a p53 response that involves p53 acetylation
KOBAYASHI, Takahiko, TING WANG, TANAKA, Junji, IMAMURA, Masahiro, HASEGAWA, Kiminori, TANAKA, Yoshiyuki, BRACHMANN, Rainer K, MAEZAWA, Masaji, KOBAYASHI, Masanobu, OHNISHI, Shunsuke, HATANAKA, Kazuteru, HIGE, Shuhei, SHIMIZU, Yuichi, KATO, Mototsugu, ASAKA, Masahiro
Published in Cancer research (Chicago, Ill.) (15.03.2006)
Published in Cancer research (Chicago, Ill.) (15.03.2006)
Get full text
Journal Article